Apollo Global Management, Inc. Reports Third Quarter 2025 Results November 4, 2025 Apollo Reports Third Quarter 2025 Results New York, November 4, 2025 – Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, "Apollo") today reported results for the third quarter ended September 30, 2025. Dividend Apollo Global Management, Inc. has declared a cash dividend of $0.51 per share of its Common Stock for the third quarter ended September 30, 2025. This dividend will be paid on No ...

Financial Performance - Q2 2025 - Adjusted Earnings Per Share decreased by 10% compared to the prior year quarter[6] - Total Segment Operating Profit was $830 million, a decrease of 10% compared to the prior year quarter, attributed to lower total segment operating profit[6] - Adjusted Return on Invested Capital (ROIC) was 69%[45] - Cash flows from operations before working capital decreased by $459 million due to lower total segment operating profit[7] Financial Performance - 1H 2025 - Adjusted Earnings Per Share was $163, a decrease of 35% compared to the prior year period[6] - Total Segment Operating Profit was $16 billion, a decrease of 26% compared to the prior year period[6] - Cash flows from operations before working capital was $12 billion[6] Segment Performance - Ag Services & Oilseeds segment operating profit declined by 17% in Q2 2025 compared to Q2 2024, with Ag Services down 7% and Crushing down 75%, while RPO rose 14%[14] - Carbohydrate Solutions segment operating profit decreased by 6% in Q2 2025 compared to Q2 2024, driven by lower international volumes and margins in Starches & Sweeteners[17] - Nutrition segment achieved an approximate 5% increase in both revenue and operating profits in Q2 2025 compared to Q2 2024, with Human Nutrition revenue up approximately 4% and Animal Nutrition revenue holding steady[24] Cash Flow and Capital Allocation - Invested $596 million in capital expenditures in 1H 2025, with capex now expected to be in the range of $13 billion - $15 billion for 2025[28] - Returned $495 million of excess cash to shareholders through dividends during 1H 2025[28] Full Year 2025 Outlook - The company expects adjusted earnings per share of approximately $400[31]

Leading the Future of Manufacturing Q3 2025 Earnings Presentation November 4, 2025 © 2025 Xometry and/or its affiliates. All rights reserved. Proprietary. Safe Harbor This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the Company's future results of operations, financial position and cash flows, expectations regarding its growth and margin expansion, including in international markets, ...

Company Overview - PJT Partners is a premier, global, advisory-focused investment bank[11] - The company's revenue for the Last Twelve Months (LTM) ending Q3 2025 was $166 billion[12] - The firm has a global presence with 15 offices[12] - The company's market capitalization is $78 billion[12] Growth and Performance - From 2015 to LTM 3Q25, the number of partners increased by 189%[29] - From 2015 to LTM 3Q25, the firmwide headcount increased by 247%[29] - From 2015 to LTM 3Q25, the total number of clients increased by 102%[29] - Revenues increased by 308% from 2015 to LTM 3Q25, reaching $1656 million[29] - Adjusted EPS increased by 309% from 2016 to LTM 3Q25, reaching $634[29] - Adjusted Pretax Income increased by 704% from 2015 to LTM 3Q25, reaching $337 million[29] Financial Highlights (Third Quarter 2025) - Revenue for the third quarter of 2025 was $447 million, a 37% increase[65] - GAAP Pretax Income for the third quarter was $91 million, an 84% increase[65] - Adjusted Pretax Income for the third quarter was $94 million, an 86% increase[65] - GAAP Diluted EPS was $147, an 86% increase[65] - Adjusted EPS was $185, a 99% increase[65] Financial Highlights (Nine Months 2025) - Revenue for the nine months of 2025 was $1179 million, a 16% increase[65] - GAAP Pretax Income for the nine months was $220 million, a 31% increase[65] - Adjusted Pretax Income for the nine months was $230 million, a 34% increase[65] - GAAP Diluted EPS was $470, a 53% increase[65] - Adjusted EPS was $443, a 43% increase[65] Financial Highlights (Last Twelve Months 3Q25) - Revenue for the last twelve months was $1656 million, a 23% increase[65] - GAAP Pretax Income for the last twelve months was $323 million, a 47% increase[65] - Adjusted Pretax Income for the last twelve months was $337 million, a 50% increase[65] - GAAP Diluted EPS was $650, a 65% increase[65] - Adjusted EPS was $634, a 56% increase[65]

Financial Performance - Third quarter revenue was $139 million, comparable to the prior year, with organic growth of 8%[13, 28] - GAAP net income was $3 million, compared to a net loss of $5 million in the prior year[23, 28, 29] - Adjusted EBITDA increased by 13% to $27 million, with Adjusted EBITDA margin expanding by over 200 basis points[23, 28] - Cash from operations nearly tripled for the quarter and is up 88% year-to-date[23] - Adjusted Gross Margin increased 50 basis points due to improved product mix[37] - Adjusted Net Income nearly tripled due to increased gross margin, decreased operating expenses, and decreased interest expense[44] Segment Performance - Pain Treatments revenue grew by 6% to $67 million, driven by strong Durolane volume growth[30, 31, 36] - Surgical Solutions revenue increased by 9% to $50 million, with growth in Bone Graft Substitutes[32, 33, 36] - Restorative Therapies revenue declined by 29% to $21 million due to the divestiture of the Advanced Rehabilitation Business, but EXOGEN grew by 11%[34, 35, 36] Strategic Initiatives - The Peripheral Nerve Stimulation (PNS) market is estimated at approximately $200 million in the U S, expected to exceed $500 million by 2029, with annual growth above 20%[20] - The company expects PNS and PRP to provide at least 200 basis points of profitable growth in 2026[22] Financial Outlook - The company reaffirmed its 2025 financial guidance, with net sales expected to be in the range of $560 million to $570 million, representing organic growth of 6% to 8%[46] - Adjusted EBITDA is projected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share in the range of $0 64 to $0 68[46]

Acquisition Overview - Intuitive Machines is acquiring Lanteris Space Systems in a transaction valued at approximately $800 million[20] - The transaction involves $450 million in cash and $350 million in Class A common stock[20] - The combined entity has a TTM (Trailing Twelve Months) revenue exceeding $850 million[20] - The combined backlog is approximately $920 million[20] Financial Highlights - Intuitive Machines has approximately $630 million in revenue (TTM Q3 2025)[16] - The company reports double-digit adjusted EBITDA margins (TTM Q3 2025)[16] - The company's backlog is approximately $685 million (as of September 30, 2025)[16] Strategic Positioning - The acquisition accelerates Intuitive Machines' three pillars: Delivery, Data, and Infrastructure from Earth to LEO/MEO/GEO to Moon, Mars[11] - The company has launched over 300 spacecraft[16] - The company has over 100 satellites in orbit today with 99.99% on-orbit availability[16] Market Opportunities - The company is targeting a $4.8 billion NASA program for lunar communications[22] - The company is targeting a $4.6 billion NASA contract to deliver and operate a lunar rover[22]

This presentation contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance; future guidance, future operating models, R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding the timing and financial impact of divestitures; di ...

Highlights (1/4) Third Quarter 2025 Financial Results Conference Call November 4, 2025 Forward-Looking Statements This presentation contains certain "forward-looking statements" (as such term is defined in Section 21E of the Securities Exchange Act of 1934, as amended). All statements, other than statements of historical facts, that address activities, events or developments that Costamare Inc. (the "Company") expects, projects, believes or anticipates will or may occur in the future, including, without lim ...

Q3 2025 Financial Performance - Global Contract Value (CV) increased by 30% to $50 billion[13] - Consolidated Revenues grew by 27% to $15 billion[13] Foreign Exchange (FX) neutral growth was 12%[13] Contribution Margin was 689%[13] - Insights Revenues increased by 51% to $13 billion[13] FX Neutral growth was 36%[13] Contribution Margin reached 767%[13] - Conference Revenues decreased by 16% to $75 million[13] FX Neutral decrease was 41%[13] Contribution Margin was 366%[13] - Consulting Revenues decreased by 32% to $124 million[13] FX Neutral decrease was 48%[13] Contribution Margin was 285%[13] - Adjusted EBITDA increased by 19% to $347 million[13] FX Neutral growth was -08%[13] Adjusted EBITDA Margin was 228%[13] - Adjusted EPS grew by 104% to $276[13] - Free Cash Flow was $269 million[13] Updated 2025 Guidance - Consolidated Revenues are projected to be at least $6475 billion[13] - Adjusted EBITDA is expected to be at least $1575 billion[13] - Adjusted EPS is projected to be at least $1265[13] - Free Cash Flow is expected to be at least $1145 billion[13] Capital Allocation - Share repurchases amounted to $11 billion[13] - Approximately $13 billion remains authorized for repurchase as of September 30, 2025[39]

Q3 2025 Performance Highlights - Waters Corporation reported Q3 2025 revenue of $800 million, with constant currency (CC) revenue growth of 8%[10] - CC recurring revenue growth was 9%[10] - CC instrument growth was 6%[10] - Q3 2025 Non-GAAP EPS grew by 16% to $3.40[10] - High single-digit (HSD) LC-MS growth and 17% CC growth were achieved[10] Growth Drivers and Innovation - BioAnalytical Characterization new products saw an 11% sequential growth in instrument sales from Q2 2025 to Q3 2025[13, 14] - Chemistry growth was 11% year-to-date in constant currency, driven by new BioSeparations products[16, 17] - Waters Alliance iS sales grew +300% in constant currency in 3Q25 compared to 3Q24[14] - Waters Xevo TQ Absolute sales grew +30% in constant currency in 3Q25 compared to 3Q24[14] Geographic and Market Performance - Pharma sales growth in Q3 2025 in constant currency was 11% overall, with strong performance across Americas, Europe, and Asia ex-China[19, 20] - Asia experienced 13% growth, Americas and Europe both saw 5% growth[34, 35] Guidance - The company projects FY 2025 constant currency revenue growth between 6.5% and 7.1%[37] - The company projects Q4 2025 constant currency revenue growth between 5.2% and 7.2%[37] - Non-GAAP EPS for FY 2025 is projected to be between $13.05 and $13.15[37] - Non-GAAP EPS for Q4 2025 is projected to be between $4.45 and $4.55[37]